NetworkNewsBreaks Archive - Page 2021 of 2065

ThursdayJan 26, 2017 1:34 pm

NetworkNewsBreaks – Kindred Biosciences, Inc.’s (NASDAQ: KIN) Strategy to Capture its Share of $7.5B Animal Health Market

Kindred Biosciences (NASDAQ: KIN) is a development-stage biopharmaceutical company taking aim at the $7.5 billion animal health market, specifically focusing on therapies for pets. The company has established a simple, yet effective, strategy to capture its share of the market: leverage investments made in human pharmaceutical R&D to develop therapies that offer the benefits of lower risk, lower cost, and shorter time-to-market. Kindred currently has in development an exciting pipeline of more than 20 programs of high-value products for dogs, cats and horses. The company’s lead candidates are Mirataz™, a weight loss product for cats, and Zimeta™ to treat fever…

ThursdayJan 26, 2017 1:31 pm

NetworkNewsBreaks – Apricus Biosciences, Inc. (NASDAQ: APRI) Continues to Advance Erectile Dysfunction Treatment on Global Scale

Apricus Biosciences (NASDAQ: APRI) is focused on advancing the development and commercialization of its innovative, life-improving treatment products in urology and rheumatology. The company’s pipeline includes Vitaros®, a locally applied topical cream for the treatment of erectile dysfunction, a condition affecting roughly 150 million men worldwide. Containing alprostadil in combination with the company’s novel excipient, Vitaros delivers a rapid onset with significant efficacy and an encouraging safety profile. In a study of more than 3,000 patients, Vitaros demonstrated positive, clinically meaningful responses in measures of erectile function. The FDA recently determined that Vitaros, under current regulations, is now considered a…

ThursdayJan 26, 2017 1:26 pm

NetworkNewsBreaks – Regulatory Approvals Mark Significant Milestones for Trendlines Group Ltd.’s (TRNLY) Gordian Surgical

Gordian Surgical, a medical portfolio company of Trendlines Group Ltd. (OTCQX: TRNLY), is making significant advances in the way surgical procedures are performed with its TroClose1200™, which in the fourth quarter of 2016 was awarded both U.S. FDA regulatory clearance and CE Mark certification. TroClose1200 was designed to provide surgeons "two-in-one" functionality. The device acts as a trocar, through which surgical instruments enter the abdomen; and as a device to close internal incisions made during surgery. It works by enabling the insertion of sutures into the tissue at the beginning of the procedure and is anchored to remain in place…

ThursdayJan 26, 2017 1:20 pm

NetworkNewsBreaks – Asterias Biotherapeutics (NYSE: AST): AST-OPC1 Efficacy Results Demonstrate Life-changing Potential for Spinal Cord Injury Patients

With an eye on FDA discussions later this year, biotech Asterias (NYSE: AST) is harnessing the potential of regenerative medicine to improve the quality of life of patients with spinal cord injuries (SCI). Recent efficacy results from the ongoing phase 1/2a clinical trial showed that SCI patients treated with the company’s AST-OPC1 cells demonstrated improved ability to use their arms, hands and fingers. Company CEO Steve Cartt in a press release called the results encouraging as Asterias plans for discussions with the FDA in mid-2017 to determine the appropriate strategy for regulatory approval. According to the World Health Organization, between…

ThursdayJan 26, 2017 1:17 pm

NetworkNewsBreaks – Fuwei Films (NASDAQ: FFHL) Shares Surge on Potential of New Polyester Film Sales Contract

Shares of Fuwei Films (NASDAQ: FFHL) are up 54% this morning on news the company has signed an annual sales contract with Eternal Electronic Material (Guangzhou) Co., Ltd., an existing costumer that purchases polyester film for printed circuit boards (PCB). Fuwei expects that the new contract for 2017 will increase the total polyester film for PCB sales in the first quarter of the year by approximately 34.5% compared to the same period of 2016. "Our company will continue to execute a portfolio of products that optimizes a higher margin strategy. We intend to continue to leverage our R&D capabilities and…

WednesdayJan 25, 2017 1:43 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 25, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: GTHP 61.69% – News: Enters exclusive distribution agreement for LuViva® Advanced Cervical Scan NBEV 10.35% – News: Launches portfolio of teas created exclusively for a major North American convenience store chain SPYR 10.14% – News: Anticipated to join eSports market in 2017 AMCT 9.09% – News: Enters into service agreement with veteran education and training consultant in China through Shenzhen subsidiary PTCO 7.13% – News: Acquires oil and gas parcels in Valley County, Montana…

WednesdayJan 25, 2017 1:40 pm

NetworkNewsBreaks – COPsync, Inc. (NASDAQ: COYN) Inks Purchase Agreement with Arecibo, Puerto Rico

COPsync (NASDAQ: COYN) is trading 6% higher following this morning’s news that it has signed a contract with the municipality of Arecibo, Puerto Rico, to provide the COPsync law enforcement communication Network™ and the COPsync911™ threat-alert system. These COPsync systems are expected to provide increased safety for the city's residents and the millions of tourists that visit Puerto Rico annually. The contract is anticipated to be the company’s largest to date once fully realized. "Arecibo is an important city in Puerto Rico. It is home to the island's milk industry and supports a thriving tourist industry. We are honored that…

WednesdayJan 25, 2017 1:36 pm

NetworkNewsBreaks – Advantage Lithium (AVLIF) Tackles Growing Lithium Demand with Strongest Drill Results to Date

Advantage Lithium (OTCQB: AVLIF) is a lithium explorer and developer with an international portfolio of quality assets. The company wrapped up 2016 with results from its Clayton NE project, in which the company drilled lithium brines on all three of its drill holes in the Clayton Valley, Nevada. Lithium brines intercepted by the third drill hole demonstrated the strongest results to date, showing peak values of 322 mg/l lithium. According to the company, the demand for lithium is growing rapidly with predicted growth to triple over the next 10 years, and it already exceeds supply by 15%. The increasing battery…

WednesdayJan 25, 2017 12:28 pm

NetworkNewsBreaks – GSI Technology, Inc. (NASDAQ: GSIT) Targets High-Performance Memory Market and In-Place Associative Compute Market

GSI Technology (NASDAQ: GSIT) historically designs, develops and markets high-performance memory products primarily for networking and telecommunication equipment manufacturers, in a market currently estimated at $500 million. More recently, it has expanded its development strategy to include RadHard SRAM targeted at aerospace and defense applications and a patented in-place associative compute solution for applications such as machine learning, image detection, speech recognition, recommender systems for e-commerce, data mining, and cyber security, a booming market with huge growth potential over the next decade and beyond. GSI is primed to capitalize on the many opportunities afforded to it by its patented in-place…

WednesdayJan 25, 2017 12:23 pm

NetworkNewsBreaks – Akebia Therapeutics, Inc. (NASDAQ: AKBA) Remains Focused on Further Development of Vadadustat

Akebia Therapeutics (NASDAQ: AKBA) is a biopharmaceutical company engaged in discovering and developing novel therapeutic solutions that leverage hypoxia inducible factor (HIF) biology, a primary regulator involved in multiple major biological pathways. According to an earlier Aegis report (http://nnw.fm/F4ezY), Akebia’s lead product candidate, vadadustat, has an impressive 60 percent probability of clinical success. Vadadustat is currently in phase III trials, after encouraging results were reported during phase II testing. In December 2016, Akebia signed a collaboration and license agreement with Otsuka Pharmaceutical (OTC: OTSKF) for vadadustat in the U.S. The companies will equally share the revenue and commercialization costs of…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks